The estimated Net Worth of George Bickerstaff is at least $5.72 Million dollars as of 14 May 2024. Mr. Bickerstaff owns over 5,255 units of Innoviva Inc stock worth over $2,036,534 and over the last 10 years he sold INVA stock worth over $3,355,950. In addition, he makes $324,994 as Independent Director at Innoviva Inc.
Sign up
Mr. Bickerstaff INVA stock SEC Form 4 insiders trading
George has made over 15 trades of the Innoviva Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,255 units of INVA stock worth $52,550 on 14 May 2024.
The largest trade he's ever made was selling 25,000 units of Innoviva Inc stock on 28 February 2022 worth over $977,750. On average, George trades about 3,045 units every 28 days since 2014. As of 14 May 2024 he still owns at least 104,976 units of Innoviva Inc stock.
You can see the complete history of Mr. Bickerstaff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
George Bickerstaff biography
George W. Bickerstaff III serves as Independent Director of the Company. He is currently a member of the Audit Committee of the Board of Directors (the "Audit Committee") and the Compensation Committee of the Board of Directors (the "Compensation Committee"). He currently serves as a Managing Director of M.M. Dillon & Co., LLC, an investment banking firm. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG. Prior to joining Novartis, Mr. Bickerstaff was the Chief Financial Officer of IMS Health, Division of Dun & Bradstreet. Mr. Bickerstaff currently serves on the board of directors of CareDx, Inc. and Cardax, Inc. Mr. Bickerstaff previously served on the board of directors of Axovant Sciences Ltd, Inovio Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. until it was acquired by Takeda Pharmaceutical Company Limited in February 2017. Mr. Bickerstaff has demonstrated leadership in his field, his understanding of our industry and his senior management experience contributed to our conclusion that he should serve as a director.
What is the salary of George Bickerstaff?
As the Independent Director of Innoviva Inc, the total compensation of George Bickerstaff at Innoviva Inc is $324,994. There are 3 executives at Innoviva Inc getting paid more, with Marianne Zhen having the highest compensation of $551,918.
How old is George Bickerstaff?
George Bickerstaff is 64, he's been the Independent Director of Innoviva Inc since 2017. There are 1 older and 6 younger executives at Innoviva Inc. The oldest executive at Innoviva Inc is Jules Haimovitz, 69, who is the Independent Director.
What's George Bickerstaff's mailing address?
George's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Insiders trading at Innoviva Inc
Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital..., and Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.
What does Innoviva Inc do?
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
What does Innoviva Inc's logo look like?
Complete history of Mr. Bickerstaff stock trades at Caredx Inc, Innoviva Inc, Inovio Pharmaceuticals Inc, and Axovant Gene Therapies
Innoviva Inc executives and stock owners
Innoviva Inc executives and other stock owners filed with the SEC include:
-
Marianne Zhen,
Chief Accounting Officer -
Marianne Zhen CPA,
Chief Accounting Officer -
Pavel Raifeld C.F.A.,
Chief Exec. Officer -
George Bickerstaff,
Independent Director -
Jules Haimovitz,
Independent Director -
Odysseas Kostas,
Independent Chairman of the Board -
Sarah Schlesinger,
Independent Director -
Mark DiPaolo,
Independent Director -
Pavel Raifeld,
Chief Executive Officer -
Paul Pepe,
Director -
Michael W Aguiar,
President & Chief Exec Officer -
Barbara Gayle Duncan,
Director -
William H Waltrip,
Director -
Theodore L Jr Witek,
Sr. VP & Chief Scientific Off. -
Cathy Friedman,
Director -
James L Tyree,
Director -
Michael E. Faerm,
Sr VP & Chief Business Officer -
George B Abercrombie,
Sr. VP & Chief Comm. Officer -
Patrick G Lepore,
Director -
Eric D Esparbes,
SVP and CFO -
Alexander J Sarissa Capital...,
-
Matthew Ronsheim,
See Remarks -
Geoffrey Hulme,
Interim Principal Exec Officer -
Deborah Birx,
Director -
Plc Gsk,
10% owner -
Derek A Small,
Director -
Sapna Srivastava,
Director -
Margaret Koziel,
Chief Medical Officer -
Stephen Basso,
Chief Financial Officer